Days after Eli Lilly and Company said it would stop a trial of its Covid-19 antibody therapy in hospitalized patients because it was not effective, the company on Wednesday published promising interim results from a trial involving patients with mild and moderate Covid-19.
More Stories
Brazil rolls out COVID-19 vaccination plan
First Pfizer COVID-19 vaccine shipments to be delivered to US distribution sites starting Monday
CDC advisory panel recommends Covid-19 vaccine for people 16 and over